MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation
Status:
Terminated
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This is an international study in adult patients diagnosed with multiple myeloma who have
already received at least one autologous stem cell transplantation and who have responded but
later progressed, or relapsed, at least one year after transplantation.
Eligible patients will be randomly assigned to one of two treatments: either Velcade plus
Thalidomide plus Dexamethasone or Thalidomide plus Dexamethasone.
Thalidomide and Velcade are two new agents that have recently become available for the
treatment of multiple myeloma, especially in relapsed patients. This study therefore aims to
test the hypothesis that the combination treatment with Velcade plus Thalidomide plus
Dexamethasone will result in a longer time to progression (measure of time after the disease
is treated until it starts to get worse) than Thalidomide plus Dexamethasone alone.
Phase:
Phase 3
Details
Lead Sponsor:
European Group for Blood and Marrow Transplantation European Society for Blood and Marrow Transplantation
Collaborators:
Celgene Corporation Johnson & Johnson Pharmaceutical Research & Development, L.L.C.